We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based biotech company Iksuda Therapeutics has executed its option to secure exclusive worldwide rights to develop a new class of tumour-activated prodrug payloads from the University of Goettingen.